INTRODUCTION
The incidence of pediatric and adolescent and young adult (AYA) cancers has increased significantly since 1975. 1, 2 Due to advances in treatments, survival for children and AYAs diagnosed with cancer has improved drastically over the past 40 years, with 5-year survival rates now exceeding 80%. [1] [2] [3] As a result, the population of pediatric and AYA survivors in the United States continues to grow, and will likely reach 500,000 by the year 2020. 4 However, survivors experience high rates of morbidity and mortality, in part due to late effects from the therapies used to treat their cancers, including chemotherapy, radiotherapy, and surgery. 5, 6 Respiratory complications are a common cause of morbidity and a leading cause of late mortality, second only to cancer, among cancer survivors. Diseases of the respiratory system are consistently a leading noncancer cause of late mortality, with survivors demonstrating a 6-fold to 15-fold excess risk of dying of a respiratory condition compared with individuals matched from the general population. [7] [8] [9] Survivors also demonstrate high rates of pulmonary dysfunction, including abnormal pulmonary function testing, chronic cough, supplemental oxygen use, fibrotic disease, and recurrent pneumonia. [9] [10] [11] [12] [13] [14] These long-term respiratory health conditions can have serious impacts on daily activities and negatively affect quality of life. 9, 11, 13 Respiratory complications, including infection, acute lung injury, and treatment effects, also are common among pediatric patients with cancer who are undergoing treatment.
Cancer October 1, 2018 costs than comparison groups drawn from the general population. [15] [16] [17] [18] Although acute respiratory events, such as asthma, represent a significant percentage of all emergency department (ED) visits among patients with cancer, respiratory-related ED use among pediatric and AYA cancer survivors has not been evaluated to date. The majority of studies investigating respiratory health among cancer survivors rely on self-reported outcomes, which are subject to recall and response bias, or on direct measures of pulmonary function rather than health care use. ED data provide an objective assessment of respiratory health outcomes, health care use, and burden in this population that is not captured through self-report or direct pulmonary function testing.
Although adverse respiratory outcomes are a common acute and long-term complication of therapy and the leading cause of noncancer mortality, to the best of our knowledge the impact of these complications on acute health care use among pediatric and AYA patients with cancer and cancer survivors has not been studied. Using ED data from 2 major health care systems, we report on respiratory health care utilization among a statewide cohort of Utah-based children and AYAs diagnosed with cancer compared with a sex-matched and birthdate-matched set of population-based controls without cancer. We used ED visits as an objective measure of poor respiratory health to better understand the burden from respiratory complications experienced by children and AYAs with cancer from the time of diagnosis through survivorship. We also identified demographic and clinical risk factors associated with respiratory ED visits among cancer cases.
MATERIALS AND METHODS
The current study was conducted as part of a larger Utahbased cohort examining short-term and long-term health outcomes for pediatric and AYA patients with cancer and cancer survivors. 15, 17 Here, we focus on the burden due to acute respiratory complications as reflected by ED visits. All study procedures and materials were approved by the University of Utah institutional review board.
Study Sample and Data Sources
We identified a cohort of pediatric and AYA patients with cancer through Intermountain Healthcare (IH; Salt Lake City, Utah), which includes Primary Children's Hospital, the only children's hospital for the state of Utah. We included individuals diagnosed from January 1, 1997 through December 31, 2012 who were aged ≤25 years at the time of diagnosis and who were diagnosed and/ or treated at Primary Children's Hospital. Cancer cases were limited to individuals with a Utah birth certificate and a defined International Classification of Childhood Cancer (ICCC) code, the standard classification system for pediatric cancers. 19 Those with nonmelanoma skin cancers and cancers in situ were excluded. A total of 2535 cases met these criteria.
Population-based controls without cancer were randomly selected from Utah birth certificates, accessed through the Utah Population Database (UPDB) at the time of diagnosis for each case. Controls had to be living in Utah at the time of diagnosis of the cancer case to be eligible for inclusion in the comparison cohort. Population controls were matched based on birthdate and sex using a 3:1 ratio of controls to cases (7605 controls).
Additional demographic data for both cases and controls were drawn from UPDB. UPDB is the only database of its kind in the United States and has records for >8 million individuals spanning the duration of their residence in Utah. UPDB includes linkages with the Utah Cancer Registry (UCR), the Utah Department of Health, and the IH and University of Utah Health Care (UUHC) systems. UPDB contains linked demographic information, residential histories, and family pedigrees as well as statewide driver license records, voter registration, and vital records for marriages, divorces, births, and deaths. 20 UCR is a population-based Surveillance, Epidemiology, and End Results program cancer registry and has maintained statewide cancer records since 1966. Records of ED visits were obtained from electronic health records for the IH and UUHC systems, which are the 2 largest health care systems in the state, capturing approximately 85% of health care encounters in Utah. Utah residency was determined through the UPDB or by the zip code provided at the time of an ED visit.
Measures
We identified respiratory visits using International Classification of Diseases, Ninth Revision (ICD-9) or International Classification of Diseases, Tenth Revision (ICD-10) codes. The first ICD-9 or ICD-10 code listed in the record was used to determine whether the ED visit was respiratory related (ICD-9 codes 460-519 or ICD-10 codes J00-J99). 21, 22 Intraoperative and postprocedural complications were excluded from the analysis. ED encounters with a primary respiratory code were flagged and then classified by the type of respiratory diagnosis: asthma, respiratory disease, or respiratory infection (see Supporting Table 1 ). We limited ED visits to include only those visits for a primary respiratory diagnosis that took place while the Cancer October 1, 2018 subject was a Utah resident based on UPDB records or by the zip code provided at the time of the ED visit.
Case-specific measures were obtained through IH and UCR and included age at diagnosis, diagnosis date, ICCC diagnosis, and whether or not the patient received chemotherapy or radiotherapy. We grouped ICCC diagnoses as leukemia, lymphoma, central nervous system neoplasms, solid tumors (neuroblastoma, retinoblastoma, renal tumors, hepatic tumors, and germ cell tumors), sarcomas/bone tumors, and epithelial neoplasms.
Using records from UPDB, IH, and UCR, we created variables for race/ethnicity, parental educational level, sex, and birthdate. Race/ethnicity was classified as either non-Hispanic white or Hispanic/other due to the small number of participants of other races/ethnicities within the cohort. Socioeconomic status was approximated using average educational attainment of the subject's parents, obtained through the UPDB from birth certificates.
Follow-Up
Follow-up for ED events was divided into 2 time periods: new cases (0 to <5 years from diagnosis) and survivorship (5-18 years from diagnosis) to observe how respiratory health may change over time. Because population controls were matched with cancer cases based on birthdate, they entered each cohort on the same date as their index case. Population controls were included in the cohort only if their case also entered the cohort. We also 
Statistical Analysis
Demographic characteristics were compared between cancer cases and population controls using chi-square and Student t test statistics. We evaluated ED visits for cancer cases and the comparison cohort using rate (visit count per year) for both follow-up periods. Analyses were conducted for all primary respiratory visits combined and stratified by the type of respiratory diagnosis: asthma, respiratory disease, or respiratory infection. An α level of .05 was used for all statistical tests. Incidence rates (IRs) were modeled using negative binomial regression using robust standard errors and allowing for correlation due to matching between cases and controls. Negative binomial regression also accommodated overdispersion in the data due to the high number of individuals with no ED events as well as the additional variability in event likelihood between subjects. 23 The absolute excess risk was calculated by subtracting the IRs of the population controls from those of the cancer cases. Rate ratios (RRs) also were modeled using negative binomial regression with robust standard errors and allowing for clustering from matching. We adjusted models for sex, race/ethnicity, birth year, and age at the time of cohort entry. Stratified models were used to assess associations between demographic characteristics and respiratory ED visits.
We used case-only models to examine demographic characteristics, treatment risk factors, and clinical risk factors for respiratory ED visits among new cases and cancer survivors. Negative binomial regression was used for both follow-up periods with adjustments made for sex, race/ethnicity, and birth year.
RESULTS
Cancer cases contributed an average of 7.57 years (standard deviation, 5.3 years) of follow-up with 0.3 ED visits (range, 0-19 ED visits), and population controls contributed 8.32 years (standard deviation, 4.7 years) of followup time with an average of 0.1 ED visits (range, 0-15 ED visits). A total of 17% of the cancer cases died during follow-up compared with 0.3% of controls, and 13% of cancer cases experienced a recurrence of their primary cancer. Other demographic and clinical characteristics are summarized in Table 1 . Compared with population controls, cancer cases were more likely to be Hispanic/ other.
The IRs for all types of respiratory ED visits were significantly greater than zero for both cancer cases and population controls over both follow-up periods ( Table 2 ). Cancer cases tended to have higher rates for all types of respiratory ED visits compared with population controls; however, the magnitude of the difference declined with increasing time from diagnosis ( Compared with Hispanic/other population controls, the RRs for Hispanic/other new cancer cases (0 to <5 years from diagnosis) were elevated for diagnoses of respiratory disease and respiratory infection (Table 3) . Male cancer cases and non-Hispanic white cases demonstrated a significantly increased risk of ED visits for any respiratory condition and due to respiratory disease and respiratory infection during all follow-up times compared with male and non-Hispanic white population controls, respectively. Non-Hispanic white survivors (5-18 years from diagnosis) also were found to be at a higher risk of all respiratory ED visits. Although female new cancer cases were at an increased risk of any respiratory ED visit and visits due to respiratory disease and respiratory infection, the risk of ED visits for female survivors did not differ from that of female population controls.
Among cancer cases (Table 4) , the risk of respiratory ED visits was significantly greater for new cases (0 to <5 years from diagnosis) who were Hispanic/other compared with cases who were non-Hispanic white (Table 4) .
New cancer cases (0 to <5 years from diagnosis) who were treated with chemotherapy had a significantly higher risk of ED visits for any respiratory cause and of visits for respiratory disease and respiratory infection. Treatment with radiotherapy tended to increase the risk of any respiratory ED visit; however, the association was not statistically significant (Table 4) . Cases diagnosed with leukemia had the highest rate of ED visits for any respiratory cause and respiratory infection during the first 5 years compared with cases with other diagnoses (Table 5) . New cases diagnosed with epithelial neoplasms were found to be at the lowest risk of respiratory infection ED visits. For new cancer cases, the risk of ED visits was highest for those diagnosed before age 10 years for any respiratory condition (0-4 years, 4 20-25 years] ). Survivors (5-18 years from diagnosis) who were diagnosed between birth and age 4 years and survivors of leukemia tended to be at higher risk of any respiratory and respiratory infection ED visits; however, the results were not statistically significant. Although survivors of lymphoma were at a higher risk of ED visits for respiratory disease, no other significant clinical risk factors were detected for asthma or respiratory disease.
DISCUSSION
We found that acute respiratory events, although particularly common among pediatric and AYA cancer cases within the first 5 years from diagnosis, remain a concerning issue into survivorship. The rates of respiratory ED visits for any cause, as well as for asthma, respiratory Cancer October 1, 2018 disease, and respiratory infection, remain elevated compared with population controls for individuals diagnosed with cancer years after diagnosis. Several demographic and clinical risk factors for respiratory ED visits also were identified. Cancer cases who were of Hispanic/other race/ ethnicity were found to be more likely to have respiratory ED visits for all types of respiratory conditions within the first 5 years from diagnosis. Males, cases diagnosed at younger ages, and cases diagnosed with leukemia also were at an increased risk of respiratory ED visits as new cancer cases and survivors. Respiratory infections were the most common reason for respiratory ED visits among children and AYAs diagnosed with cancer over both time periods. This is consistent with prior studies based on self-reported respiratory health among survivors, which found high rates of respiratory infections, such as recurrent pneumonia. 9, 10 Because respiratory infections appear to cause the most burden on pediatric and AYA patients with cancer and cancer survivors, both in terms of risk and rate of ED visits, they are a promising target for potential interventions and risk-based care.
We also observed a 2-fold increase in the risk of ED visits for respiratory infections during the first 5 years from diagnosis for cases who were treated with chemotherapy. Infections cause the most significant complications in pediatric patients, with several common and opportunistic infections observed particularly while these individuals are undergoing chemotherapy. 12 Although exposure to chemotherapy resulted in a 2-fold to 3-fold increase in the risk of all types of respiratory ED visits except asthma, we did not observe any significant associations with respiratory ED visits among survivors. This was unexpected because many antineoplastic drugs, including alkylating agents (bleomycin, carmustine, and busulfan), are associated with adverse respiratory outcomes. However, several recent studies regarding late respiratory morbidity among pediatric cancer survivors also have failed to observe significant associations with chemotherapy exposure, instead finding that lung radiotherapy and surgery appear to have Abbreviations: 95% CI, 95% confidence interval; ED, emergency department; RR, rate ratio.
a RRs compared survivors with controls (referent), and were adjusted for sex, birth year, race/ethnicity, and age at time of cohort entry; cells were left blank when there were insufficient events for estimation of RRs.
b P < .05.
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the greatest impact on long-term respiratory health. 9, 11, 24 This also could be due to an increased awareness of the respiratory complications associated with these drugs. Carmustine is not typically used, and while busulfan, which is used extensively in bone marrow transplant, and bleomycin are more common, current protocols require close monitoring of pulmonary function during therapy to judge whether doses are safe. The findings of the current study demonstrate promise for survivors treated with chemotherapy, in that some of the risk of adverse respiratory outcomes could decline over time.
We also observed several demographic risk factors for ED visits for respiratory conditions among children and AYAs diagnosed with cancer, including sex, race/ethnicity, and parental educational level. The impact of race/ ethnicity was most pronounced during the first 5 years from diagnosis when cases who were Hispanic/other were found to be at an increased risk of respiratory ED visits. This is consistent with prior research indicating that children of low socioeconomic status and Hispanic/other children have restricted access to care and are less likely to have a normal source of care, potentially contributing to increased ED use to meet health care needs. 25, 26 In addition, earlier reports from our team have demonstrated that Hispanic children with cancer show an increased risk of infection-related death. 27 Respiratory infections could potentially be a significant contributor because we observed a >2-fold increase in the risk of ED visits for respiratory infections among cases who were Hispanic/other. This supports the idea that poorly controlled or more severe infections play a significant role in the observed higher infection-related mortality. Cancer October 1, 2018
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The current assessment has certain limitations. There were relatively few ED events, particularly for asthma and respiratory disease. Electronic ED records were available beginning in 1997, thereby restricting our maximum follow-up time to 18 years, with an average of 8 years of follow-up. In addition, because data were collected from secondary sources, we did not have information regarding tobacco exposure, which greatly influences respiratory health. However, Utah is consistently ranked among the lowest for prevalence of tobacco use Abbreviations: 95% CI, 95% confidence interval; CNS, central nervous system; ED, emergency department; RR, rate ratio. a RRs were adjusted for sex, birth year, and race/ethnicity; cells were left blank when there were insufficient events for estimation of RRs.
b Referent was age 20 to 25 years at time of diagnosis.
c P < 0.05.
d Referent was epithelial neoplasms.
Cancer October 1, 2018 in the United States, making it unlikely that a significant percentage of the current study cohort smoke or are exposed to secondhand smoke. 28 Treatment history was limited, thereby prohibiting our ability to investigate specific chemotherapy agents with known respiratory health outcomes as well as the impact of specific sites of radiotherapy receipt. We were unable to assess any potential impact that insurance type could have on the rate of ED visits because it was not available for the full cohort. Our ED visits were limited to the 2 main Utah health systems, IH and UUHC, meaning that we missed ED visits occurring outside of these systems. However, the IH and UUHC systems serve an estimated 85% of Utah's population, and therefore we believe we captured the vast majority of these encounters.
Children and AYAs diagnosed with cancer face an increased risk of poor respiratory health leading to increased health care use and burden of respiratory disease from diagnosis onward. The results of the current study demonstrate that health care use for respiratory complications is highest within the first 5 years from diagnosis, particularly for males, cases who are of Hispanic/other race/ethnicity, and those diagnosed with leukemia or at younger ages. This has implications for both patients and providers. Patients with cancer and cancer survivors should be educated regarding their higher risk of poor respiratory health and which behaviors could potentially lower this burden. In addition, because the risk of ED visits for respiratory infections remained significantly elevated for cases at all time points, in addition to being the most common respiratory diagnosis, there is potential for decreasing the burden on pediatric and AYA patients with cancer and cancer survivors by implementing interventions designed to decrease infection risks.
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